The PennZone

  • Home
  • Entertainment
  • Marketing
  • Non-profit
  • Music
  • Education
  • Books
  • Sports
  • Artificial Intelligence

MYONEX ANNOUNCES ACQUISITION OF SAVEWAY COMPOUNDING PHARMACY TO EXPAND ITS CLINICAL TRIAL SERVICES ACROSS THE US USA - English USA - español USA - English
The PennZone/10266682

Trending...
  • From Temecula Wine Country to Canyon Lake: Parkway Construction Transforms Outdoor Spaces for Inland Homeowners
  • Tim Tebow to Headline BSI CORE Annual Summit, Bringing Nearly 400 Business Leaders Together at Bethlehem's SteelStacks
  • RAS AP Consulting Spotlights Managed AP Governance™ at Esker All Access
HORSHAM, Pa., April 9, 2024 ~ Myonex, a leading global clinical trial supply company, has recently announced the completion of its acquisition of SaveWay Compounding Pharmacy in Newark, Delaware. The pharmacy will now operate as SaveWay Compounding Pharmacy, a Myonex company.

This strategic move by Myonex is part of their ongoing efforts to support clinical trial sponsors' trial designs with direct-to-patient (DTP) and home healthcare provider (HHP) capabilities. With this acquisition, Myonex aims to provide wider patient access across the entire United States and support patients in obtaining the necessary trial medication and equipment.

According to James Lovett, Chief Executive Officer at Myonex, "SaveWay's pharmacy capabilities complement and extend our existing clinical supplies solutions within the US. SaveWay will provide additional access for drug sourcing and direct-to-patient options across all 50 states for our clinical packaging and labeling and ancillary supply services." This will also complement Myonex's market-leading CTRx™ to offer a full suite of prescription-based supply options for both investigational medicinal product (IMP) and commercial drug access throughout the US. These added capabilities will enable Myonex to better serve their clients' needs and facilitate decentralized clinical trials (DCT) and hybrid studies.

More on The PennZone
  • Award-Winning Author's New Timely Book "Philly Girl" Highlights Centuries of Brave & Bold Women from Philadelphia
  • RAS AP Consulting Signals Growth of Managed AP Governance With Digital Expansion, Pipeline Activation, and Trademark Filing Ahead of Esker All Access
  • National Nonprofit Lights 200 Landmarks Pink and Blue for Pregnancy and Infant Loss Awareness Month
  • Vegan Kingz Unveils Upgraded Digital Platform to Streamline Commercial Foodservice & Wholesale Ordering
  • Steve Thompson Launches StickyHealth to Tackle the Retention Gap in the Growing GLP 1 Market

The acquisition also presents an opportunity for SaveWay to expand into the realm of clinical trials and accelerate the growth of their direct-to-patient services. Pradeep Chilakapati, RPh, Managing Partner and Pharmacist at SaveWay, expressed excitement about this partnership: "We welcome the opportunity to be part of an experienced clinical trial supply company with its roots in pharmacy. Myonex understands how we work and what we can offer to support today's trends in clinical trials."

This recent acquisition announcement comes on the heels of another significant acquisition by Myonex – that of Creapharm – further solidifying their commitment to providing faster, more flexible, and reliable services to their clients while improving the clinical trial patient experience. With these acquisitions, Myonex now boasts one of the most diverse clinical trial supply service offerings globally.

Myonex was exclusively advised by Crosstree as its financial advisor and Troutman Pepper as its legal advisor in this acquisition of SaveWay. This partnership is expected to bring about significant growth and success for both companies in the clinical trial supply industry.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • New Townhome Building Released at Heritage at South Brunswick, Offering Private Perimeter Setting and Water Views
  • Comics Veteran on Return of Teenage Mutant Ninja Turtles Characters, 3-D Projects, Collaboration with Original 'Star Wars' Toy Engineer
  • Flexible Plan Investments Announces Retirement of Executive Vice President Renée Toth
  • Sensory Education launches new neuro-affirming psychoeducation book, Sensory Diversity
  • Break the Resume Mold: Career Valet Changes How Executives Hunt for Jobs
  • Expansive New Worlds Await Peter Darrach Unveils 'The Cleopard and Other Tales from the Second Skin
  • James Dooley Named King of AEO at Ceremony in Leigh, England
  • Calling all healthcare process experts: Share your ideas at #HSPI2027 in Orlando
  • Data Ideology Achieves Elite Partner Status with Snowflake
  • Central Bag Company Partners with WYSIWYG Marketing and Launches a Modern Industrial Website
  • DuoKey launches the World's First Agentic Crypto Agility Platform
  • Counterparts Exhibition - Art is Destiny!
  • Sales Blueprint Architect Launches, Helping Sales Professionals, Business Owners, and Consultants Close More Business With AI
  • Parksy (parksy.com) Tackles the Most Common Parking Problem Nobody Talks About: Finding the Car Again
  • 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses
  • INAD Warriors' 4th Annual "Dancing with the INAD Stars" Gala
  • DAZN Review 2026: Streaming Price Worth It?
  • Michael Fischer, President and CEO of Client 1st Financial, Named to LVB 300
  • Easwe Lightweight Electric Wheelchair Collection with Travel-Focused Mobility Solutions
  • Dr. Pen Official Introduces Advanced Microneedling Technology for Precision Skincare at Home

Popular on PennZone

  • Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 1280
  • Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man - 163
  • Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event - 136
  • FindCostSeg Launches Nationwide Directory for Cost Segregation Providers - 125
  • Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Board of Directors
  • Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
  • Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
  • Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
  • L2 Aviation and Gotonomi Extend UAV Connectivity Beyond Cellular Reach
  • Why Baton Rouge's Humid Climate Can Contribute to Carpenter Ant Damage — J&J Exterminating Explains How to Protect Your Home

Similar on PennZone

  • Volant Announces Major Partnership with the STEM Racing Canada Program to CHAMPION YOUTH ENGINEERING
  • 54 Million Contract. New Chapter as AI Cybersecurity Platform Expands, Margins Surge & Management Signals Confidence. Cycurion, Inc: (NAS DAQ: CYCU)
  • Work 365 Deepens TD SYNNEX Integration with Automated Azure Billing
  • RAS AP Consulting Signals Growth of Managed AP Governance With Digital Expansion, Pipeline Activation, and Trademark Filing Ahead of Esker All Access
  • Break the Resume Mold: Career Valet Changes How Executives Hunt for Jobs
  • Data Ideology Achieves Elite Partner Status with Snowflake
  • Sales Blueprint Architect Launches, Helping Sales Professionals, Business Owners, and Consultants Close More Business With AI
  • RAS AP Consulting Spotlights Managed AP Governance™ at Esker All Access
  • ANSI BSR Upholds Appeal of AFDE Member Andrew Sulner, MSFS, JD, finding the AAFS Academy Standards Board (ASB) Violated ANSI Essential Requirements
  • StockResearch AI Initiates Coverage on Apple (AAPL) With New Report Examining Valuation, AI Strategy and Future Growth
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us